Sec Form 4 Filing - Tucker John H @ scPharmaceuticals Inc. - 2020-06-30

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Tucker John H 2. Issuer Name and Ticker or Trading Symbol scPharmaceuticals Inc. [ SCPH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President and CEO (Last) (First) (Middle) C/O SCPHARMACEUTICALS INC., 2400 DISTRICT AVENUE, SUITE 310 3. Date of Earliest Transaction (MM/DD/YY) 06/30/2020 (Street) BURLINGTON, MA01803 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/30/2020 M 42,250 A 47,250 D Common Stock 06/30/2020 F 10,288 ( 2 ) D $ 7.36 36,962 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Units ( 1 ) 06/30/2020 M 42,250 ( 3 ) ( 3 ) Common Stock 42,250 $ 0 0 D Stock Option (right to buy) $ 3.25 06/30/2020 A 42,250 ( 4 ) 02/25/2029 Common Stock 42,250 $ 0 42,250 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Tucker John H C/O SCPHARMACEUTICALS INC. 2400 DISTRICT AVENUE, SUITE 310 BURLINGTON, MA01803 X President and CEO Signatures /s/ John Tucker 07/02/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. ( 2 )The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units. ( 3 )On February 25, 2019, the Reporting Person was granted 84,500 restricted stock units (the "RSUs"). One half (1/2) of the RSUs shall vest upon the Issuer's submission of a New Drug Application ("NDA") for its product candidate, FUROSCIX and the remaining one half (1/2) shall vest upon the Food & Drug Administration's (the "FDA") approval of the NDA. On June 30, 2020, the performance criteria for the first half of the grant was met and 42,250 shares vested. ( 4 )On February 25, 2019, the Reporting Person was granted an option to purchase 84,500 shares of common stock. One half (1/2) of the shares shall vest upon the Issuer's submission of an NDA for its product candidate, FUROSCIX and the remaining one half (1/2) shall vest upon the FDA's approval of the NDA. On June 30, 2020, the performance criteria for the first half of the grant was met and 42,250 shares vested.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.